Platelet-rich plasma in regenerative medicine

2014 ◽  
Vol 1 (1) ◽  
Author(s):  
Guhta Ra Hara ◽  
Thaha Basu
2021 ◽  
pp. 088391152199640
Author(s):  
Renata Aquino de Carvalho ◽  
Valmir Vieira Rocha Júnior ◽  
Antonio José Felix Carvalho ◽  
Heloisa Sobreiro Selistre de Araújo ◽  
Mônica Rosas Costa Iemma ◽  
...  

Bone regenerative medicine (BRM) aims to overcome the limitations of conventional treatments for critical bone defects by developing therapeutic strategies, based on temporary bioactive substitutes, capable of stimulating, sustaining, and guiding tissue regeneration. The aim of this study was to validate the “proof of concept” of a cellularized bioactive scaffold and establish its potential for use in BRM. For this purpose, three-dimensional scaffolds of poly-(lactic acid) (PLA), produced by the additive manufacturing technique, were incorporated into a human platelet-rich plasma (PRP-h) fibrin matrix containing human infrapatellar fat pad mesenchymal stem cells (hIFPMSC). The scaffolds (PLA/finbrin-bioactive) were kept under ideal culture conditions in a medium free from fetal bovine serum and analyzed at 5 and 10 days by Scanning Electron Microscopy (SEM), Fourrier Transform Infrared (FTIR), Circular Dichroism and fluorescence microscopy. The results demonstrated the feasibility of obtaining a rigid, cytocompatible, and cellularized three-dimensional structure. In addition, PRP platelets and leukocytes were able to provide a bioactive environment capable of maintaining the viability of hIFPMSC into scaffolds. The results validate the concept of a customizable, bioactive, cellularized, and non-immunogenic strategy for application in BRM.


2018 ◽  
Vol 43 (3) ◽  
pp. 803-814 ◽  
Author(s):  
Pouria Samadi ◽  
Mohsen Sheykhhasan ◽  
Hamed Manoochehri Khoshinani

2020 ◽  
Vol 130 (6) ◽  
pp. 666-671
Author(s):  
Tatsuto Kageyama ◽  
Ayaka Nanmo ◽  
Lei Yan ◽  
Tadashi Nittami ◽  
Junji Fukuda

2020 ◽  
Vol 15 (6) ◽  
pp. 1775-1787
Author(s):  
Lisa Ann Fortier ◽  
Laurie Ruth Goodrich ◽  
Iris Ribitsch ◽  
Lauren Virginia Schnabel ◽  
David Owen Shepard ◽  
...  

Regenerative medicine is commonly used in human and equine athletes. Potential therapies include culture expanded stem cells, stromal vascular fraction of adipose tissue, platelet-rich plasma, bone marrow concentrate, or autologous conditioned serum. The purpose of this manuscript is to disseminate findings from a workshop on the development of translational regenerative medicine in the equine field. Five themes emerged: stem cell characterization and tenogenic differentiation; interactions between mesenchymal stem cells, other cells and the environment; scaffolds and cell packaging; blood- and bone marrow-based regenerative medicines; clinical use of regenerative therapies. Evidence gained through the use of regenerative medicine applications in the horse should continue to translate to the human patient, bringing novel regenerative therapies to both humans and horses.


2020 ◽  
pp. 1-7
Author(s):  
Hemamalini Narasimhan ◽  
◽  
Utkrist Lahoria ◽  

Introduction: Geriatric aesthetics is an evolving branch of cosmetology with extensive research conducted to minimize the invasiveness, number of visits and safety of the proposed modality. In developing country, the adding burden of cost hinders the practical application of standard aesthetic procedures used elsewhere. Platelet-rich plasma is an autologous preparation that is utilized in various fields of regenerative medicine.


2020 ◽  
Vol 24 (3) ◽  
pp. 211-221 ◽  
Author(s):  
Chih-Chieh Lin ◽  
Yun-Ching Huang ◽  
Wei-Chia Lee ◽  
Yao-Chi Chuang

Interstitial cystitis/bladder pain syndrome (IC/BPS), which is characterized by bladder pain and irritative voiding symptoms, is a frustrating disease without effective treatment. The cause is still largely not understood, although urothelium ischemia/hypoxia, apoptosis, denudation, and infiltration of inflammatory cells are common histopathological findings. The current uncertainty regarding the etiology and pathology of IC/BPS has a negative impact on its timely and successful treatment; therefore, the development of new treatment modalities is urgently needed. Herein, we present advances in our knowledge on this topic and review the potential application of regenerative medicine for the treatment of IC/BPS. This article provides information on the basic characteristics and clinical evidence of stem cells, platelet-rich plasma (PRP), and low-energy shock waves (LESWs) based on a literature review with a search strategy for articles related to IC/BPS, stem cells, PRP, and LESW published in MEDLINE and PubMed. Stem cells, PRP, and LESW, which modulate inflammatory processes and promote tissue repair, have been proven to improve bladder regeneration, relieve bladder pain, inhibit bladder inflammation, and increase bladder capacity in some preclinical studies. However, clinical studies are still in their infancy. Based on the mechanisms of action of stem cells, PRP, and LESW documented in many preclinical studies, the potential applications of regenerative medicine for the treatment of IC/BPS is an emerging frontier of interest. However, solid evidence from clinical studies remains to be obtained.


2020 ◽  
pp. 9-13
Author(s):  
Calvin Rong Chen

Background: Platelet-rich plasma (PRP) has become a main component of regenerative medicine. It is used in various musculoskeletal tendinous and skeletal injuries, however, literature regarding PRP’s use in chronic anterior ankle pain is limited. Objectives: To determine the effectiveness of PRP in treating tibialis anterior (TA) tendon pain in patients who have failed traditional conventional therapeutic treatments. Study Design: Retrospective chart review. Setting: Outpatient interventional pain clinic at an academic center. Methods: Adults (n = 10), aged 18 and older, with greater than 6 months of TA tendon pain who failed conservative therapies. Patients who had undergone previous regenerative injections were excluded. PRP injection was administered with ultrasound guidance. Change in pain score was assessed using the Numeric Rating Scale (NRS-11: 0 = no pain, 10 = excruciating pain), and patient’s self-reported reduction in pain (percentage), pre- and postprocedure. There was a reduction in opioid dosage postprocedure. Adverse effects were recorded. Results: Average pain score at baseline was 8 ± 1.5 on the NRS-11 scale. The average percent change in pain between baseline and 8 weeks posttreatment was a 36% ± 23.2% reduction in pain. This was a significant reduction in pain score at 8 weeks post-PRP treatment when compared with baseline, P = 0.008. Average reduction in opioid dose between baseline and 8 weeks posttreatment was 17% ± 21.2%, P = 0.063. No patients experienced adverse effects. Limitations: Small sample size, and no doubleblind randomization with control group. Conclusions: PRP use in chronic TA pain 8 weeks post-PRP treatment significantly improved chronic TA pain. There is also a tendency toward lower opioid pain medication dosages after 8 weeks post-PRP treatment, although this was not statistically significant. Key words: Platelet-rich plasma, regenerative medicine, pain, ultrasound


Sign in / Sign up

Export Citation Format

Share Document